» Articles » PMID: 37355345

Weight a Minute: Exploring the Effect on Weight and Body Composition After the Initiation of Elexacaftor/tezacaftor/ivacaftor in Adults with CF

Overview
Journal J Cyst Fibros
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2023 Jun 24
PMID 37355345
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Life expectancy for people with CF (PwCF) continues to increase. However, a trend of overweight and obesity is emerging along with concern of developing comorbitities. Body composition (BC) is associated with several health indices. However, body mass index (BMI) does not provide information on BC.

Methods: BMI, fat mass (FM), fat free mass (FFM), using bioelectrical impedance, lung function and sweat chloride (SwCl) were assessed in adult PwCF in routine clinic before and after commencement of the CFTR modulator Elexacaftor/Tezacaftor/Ivacaftor.

Results: 109 PwCF (76 male) underwent assessments at both time points. In all PwCF a significant upward trend in BMI was observed (p < 0.001). Males significantly gained more FFM compared to females (p0.03), whilst prevalence of normal weight obesity increased primarily in females (25-38%).

Conclusion: Routine BC assessment identifies individuals with elevated FM or depleted FFM enabling individualised care with the focus of optimising BC.

Citing Articles

Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A Cross-Sectional Single-Centre Study.

Clayton L, Shepherd A, Corbett J, Gruet M, Connett G, Allenby M Pediatr Pulmonol. 2025; 60(3):e71044.

PMID: 40071679 PMC: 11898567. DOI: 10.1002/ppul.71044.


Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients.

Garcia M, Pelaez A, Punter R, Lopez M, Carbajal C, Ancochea J BMC Pulm Med. 2025; 25(1):81.

PMID: 39962495 PMC: 11831831. DOI: 10.1186/s12890-024-03455-2.


Increased fat mass and obesity risk after elexacaftor-tezacaftor-ivacaftor therapy in young adults with cystic fibrosis.

Merino Sanchez-Canete A, Lopez Cardenes C, Vicente Santamaria S, Gutierrez Martinez J, Suarez Gonzalez M, Alvarez Merino M Front Nutr. 2024; 11:1477674.

PMID: 39582664 PMC: 11582979. DOI: 10.3389/fnut.2024.1477674.


Impact of Elexacaftor-Tezacaftor-Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study.

Hevilla F, Porras N, Giron M, Garcia-Olivares M, Padial M, Sanchez-Torralvo F Nutrients. 2024; 16(19.

PMID: 39408260 PMC: 11478662. DOI: 10.3390/nu16193293.


Safety and tolerability of a low glycemic load dietary intervention in adults with cystic fibrosis: a pilot study.

Scully K, Truex L, Brennan A, Fowler R, Sawicki G, Uluer A Front Nutr. 2024; 11:1441201.

PMID: 39385793 PMC: 11462092. DOI: 10.3389/fnut.2024.1441201.